Short answer
Theravance Biopharma, Inc. (TBPH) filed an 8-K current report with the SEC on September 23, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.01 (Completion of Acquisition or Disposition of Assets), Item 3.03 (Material Modification to Rights of Security Holders), Item 5.01 (Changes in Control of Registrant), Item 5.02 (Departure/Election of Directors or Officers), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Item 1.01 contains no standalone agreement terms.
Theravance Biopharma, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Item 1.01 contains no standalone agreement terms
- Material transaction details reside in Items 2.01 and 5.02 of the same filing
Item 2.01 · Completion of Acquisition or Disposition of Assets
- Merger completed under the Merger Agreement, with the surviving company’s governing documents becoming effective
- Surviving company renamed Theravance Biopharma, Inc., confirming post-closing corporate identity
- Amended articles reflect authorized share capital consistent with the merger plan
- New indemnification provisions added for specified merger-related protections
Item 3.03 · Material Modification to Rights of Security Holders
- Merger completion eliminated existing Ordinary Shareholder rights at the Effective Time
- Shareholders retained only the right to receive the Per Share Merger Consideration
- Event represents a material change in ownership rights tied to the merger transaction
Item 5.01 · Changes in Control of Registrant
- Merger completion triggered a change in control of Theravance Biopharma
- TBPH became a wholly owned subsidiary of Parent, removing standalone public-company status
- Parent funded the transaction with cash on hand and new debt financing
- Transaction details and related governance changes incorporated from Items 2.01, 5.02 and 5.03
Item 5.02 · Departure/Election of Directors or Officers
- Item 5.02 disclosure appears incomplete, limiting assessment of officer departures or appointments
- Introductory Note referenced for potentially material executive changes and compensation arrangements
Item 8.01 · Other Events
- Non-tradeable CVRs tied to ampreloxetine monetization, with no equity, voting or dividend rights
- Holders receive pro rata 80% of net proceeds from qualifying transactions within 10 years after merger completion
- First U.S., UK, Spain, France, Germany or Italy commercial sale triggers potential $50 million cash payment
- Holders receive 10% of qualifying net sales through the later of 10 years, patent expiration or loss of exclusivity
- Payments remain highly speculative, dependent on future transactions, approval, commercialization and sales performance
Item EX-99.1 · Exhibit EX-99.1
- Merger consideration includes one nontransferable CVR per ordinary share and eligible equity-award share
- CVRs provide $0.93 per CVR upon first commercial sale in the United States, United Kingdom, Spain, France, Germany or Italy
- Holders receive 80% of net license proceeds from ampreloxetine transactions completed within 10 years after closing
- Holders receive royalties equal to 10% of net ampreloxetine sales during the applicable royalty term
- Equity-award CVRs become ineligible for payments occurring more than five years after closing under Section 409A restrictions
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Theravance Biopharma, Inc. 8-K filings
Get the next TBPH 8-K as it lands
Follow TBPH for push alerts, or ask the research agent what this filing means.